VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ABT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ABTAbbott Laboratories
$104.71$182.4B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksABTFinancials

Abbott Laboratories (ABT) Income Statement

30Y historyFree accessUpdated daily

Revenue growth has been uneven, with the latest quarter's 14.5% year-over-year increase following much slower prior growth, while gross margin improved to 56.8% but operating margin fell to 10.4% from 19.6% a year earlier, suggesting rising operating expenses are eroding gross profit gains.

Income StatementBalance SheetCash FlowRatios

ABT Income Statement

Annual statement

ABT Income Statement

Abbott Laboratories (ABT) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue48.23B44.33B41.95B40.11B43.65B43.08B34.61B31.9B30.58B27.39B20.85B20.41B20.25B21.85B39.87B38.85B35.17B30.77B29.53B25.91B22.48B22.34B19.68B19.68B17.68B16.29B13.75B13.18B12.48B11.88B11.01B
Revenue Growth %10%5.67%4.59%-8.12%1.34%24.47%8.48%4.34%11.64%31.35%2.2%0.78%-7.33%-45.21%2.63%10.48%14.31%4.19%13.94%15.3%0.62%13.51%-0%11.29%8.59%18.47%4.31%5.61%5%7.9%10%
Cost of Goods Sold20.72B19.72B20.63B20.07B21.33B19.86B17.23B15.21B14.76B14.32B9.61B9.45B9.76B9.8B10.64B15.41B14.57B13.15B12.48B11.33B9.63B10.47B8.88B9.47B8.51B7.75B6.24B5.98B5.39B5.05B4.73B
COGS % of Revenue-44.49%49.17%50.04%48.86%46.11%49.79%47.68%48.25%52.3%46.08%46.29%48.19%44.86%26.68%39.67%41.44%42.73%42.28%43.71%42.86%46.86%45.14%48.14%48.1%47.58%45.39%45.36%43.23%42.46%42.97%
Gross Profit27.51B24.61B21.32B20.04B22.32B23.21B17.38B16.69B15.82B13.07B11.24B10.96B10.49B9.86B10.85B23.44B20.59B17.62B17.04B14.59B12.84B11.87B10.8B10.21B9.18B8.54B7.51B7.2B7.08B6.84B6.28B
Gross Margin %57.04%55.51%50.83%49.96%51.14%53.89%50.21%52.32%51.75%47.7%53.92%53.71%51.81%45.12%27.22%60.33%58.56%57.27%57.72%56.29%57.14%53.14%54.86%51.86%51.9%52.42%54.61%54.64%56.77%57.54%57.03%
Gross Profit Growth %-15.39%6.43%-10.24%-3.84%33.59%4.1%5.5%21.1%16.2%2.59%4.48%6.42%-9.19%-53.7%13.83%16.88%3.37%16.85%13.58%8.18%9.96%5.77%11.21%7.51%13.71%4.26%1.65%3.59%8.86%10.46%
Operating Expenses20.28B16.59B14.47B13.6B13.96B14.01B12.09B12.1B11.98B11.09B8B8.01B7.57B7.71B8.85B16.6B13.54B11.05B10.96B9.64B8.51B7.22B6.62B6.78B5.54B6.64B4.25B4.05B3.97B3.99B3.66B
OpEx % of Revenue-37.42%34.5%33.91%31.98%32.53%34.92%37.93%39.18%40.5%38.34%39.26%37.41%35.29%22.19%42.73%38.51%35.91%37.1%37.2%37.84%32.33%33.63%34.47%31.33%40.79%30.88%30.74%31.78%33.55%33.27%
Selling, General & Admin14.64B12.38B11.65B10.88B11.11B11.28B9.67B9.69B9.69B8.96B6.64B6.64B6.29B6.34B7.3B12.54B9.97B8.3B8.27B7.24B6.28B5.41B4.92B5.05B3.98B3.73B2.89B2.86B2.74B2.68B2.46B
SG&A % of Revenue-27.92%27.77%27.13%25.45%26.18%27.94%30.38%31.69%32.73%31.83%32.55%31.06%29.02%18.32%32.27%28.35%26.99%28%27.93%27.94%24.22%25.01%25.66%22.5%22.93%21.05%21.68%21.99%22.59%22.33%
Research & Development3.29B2.96B2.82B2.72B2.85B2.74B2.42B2.41B2.29B2.13B1.36B1.37B1.29B1.37B1.54B4.06B3.57B2.74B2.69B2.4B2.23B1.81B1.7B1.73B1.56B1.58B1.35B1.19B1.22B1.3B1.2B
R&D % of Revenue-6.67%6.73%6.78%6.53%6.36%6.99%7.55%7.48%7.78%6.51%6.71%6.35%6.28%3.87%10.45%10.16%8.92%9.11%9.27%9.9%8.11%8.62%8.81%8.83%9.69%9.83%9.06%9.79%10.96%10.94%
Other Operating Expenses4M1.25B00000000000000000000000000000
Operating Income7.23B8.05B6.83B6.43B8.36B9.2B5.29B4.59B3.84B1.97B3.25B2.95B2.92B2.15B2.01B6.84B7.05B6.57B6.09B4.95B4.34B4.65B4.18B2.97B3.15B1.89B3.4B3.15B3.12B2.85B2.62B
Operating Margin %15%18.16%16.27%16.04%19.16%21.36%15.29%14.39%12.57%7.2%15.58%14.45%14.4%9.82%5.03%17.61%20.05%21.36%20.62%19.08%19.29%20.81%21.23%15.11%17.82%11.63%24.74%23.9%24.99%23.99%23.76%
Operating Income Growth %-17.92%6.06%-23.04%-9.11%73.88%15.25%19.43%94.93%-39.3%10.17%1.13%35.88%6.93%-70.66%-2.97%7.31%7.91%23.12%14.05%-6.74%11.3%40.46%-5.65%66.41%-44.3%7.98%1.01%9.38%8.92%9.83%
EBITDA11.02B11.16B10.04B9.68B11.63B12.74B8.62B7.61B7.12B4.99B4.6B4.42B4.39B3.66B4.79B9.89B9.68B8.66B7.93B6.8B5.89B6.01B5.47B4.1B4.2B3.06B4.23B3.98B3.9B3.58B3.3B
EBITDA Margin %22.86%25.19%23.94%24.13%26.64%29.57%24.9%23.84%23.29%18.23%22.07%21.67%21.68%16.76%12.01%25.44%27.51%28.15%26.85%26.24%26.23%26.9%27.77%20.84%23.72%18.8%30.76%30.18%31.27%30.11%29.99%
EBITDA Growth %0.97%11.16%3.77%-16.78%-8.71%47.81%13.32%6.78%42.64%8.5%4.09%0.73%19.85%-23.55%-51.54%2.17%11.72%9.24%16.58%15.36%-1.89%9.92%33.27%-2.24%37.02%-27.58%6.3%1.93%9.05%8.33%12%
D&A (Non-Cash Add-back)3.79B3.12B3.22B3.24B3.27B3.54B3.33B3.01B3.28B3.02B1.35B1.47B1.47B1.52B2.78B3.04B2.62B2.09B1.84B1.85B1.56B1.36B1.29B1.13B1.04B1.17B827.43M828.01M784.24M727.75M686.09M
EBIT7.28B8.81B7.62B7.36B8.62B8.62B5.68B4.89B3.6B3.11B1.72B3.36B2.68B2.09B714M6.22B6.51B7.4B6.38B5.06B2.69B4.86B4.33B3.07B3.26B3.22B3.4B3.15B3.12B2.83B2.62B
Net Interest Income-706M-111M-259M-313M-132M-367M-662M-724M-624M-756M-205M-73M-87M20M-350M-932.95M-695.68M-72.88M-327.25M-456.39M-292.35M-153.66M-149.09M00000000
Interest Income237M230M344M385M183M43M46M94M105M124M99M105M77M67M59M85.2M105.45M137.78M201.23M136.75M00000000000
Interest Expense943M341M603M698M315M410M708M818M729M880M304M178M164M47M409M1.02B801.13M210.66M528.47M593.14M416.17M241.35M200.21M146.12M205.22M234.76B23.22M0000
Other Income/Expense-671M418M188M229M-56M-989M-323M-514M-971M259M-1.84B234M-398M-105M-1.7B-1.64B-1.34B623.03M-232.81M-475.9M-2.06B-29.48M-51.73M411.88M143.27M-10.88M415.83M247.53M123.98M84.17M52.44M
Pretax Income6.56B8.47B7.01B6.66B8.31B8.21B4.97B4.08B2.87B2.23B1.41B3.18B2.52B2.52B6.26B5.2B5.71B7.19B5.86B4.47B2.28B4.62B4.13B3.73B3.67B1.88B3.82B3.4B3.24B2.95B2.67B
Pretax Margin %13.61%19.1%16.72%16.61%19.03%19.06%14.36%12.78%9.4%8.15%6.78%15.6%12.44%11.54%15.71%13.38%16.25%23.38%19.83%17.25%10.13%20.68%20.96%18.98%20.77%11.56%27.76%25.78%25.97%24.82%24.24%
Income Tax1.86B1.94B-6.39B941M1.37B1.14B497M390M539M1.88B350M577M797M138M300M470M1.09B1.45B1.12B863.33M559.62M1.25B949.76M981.18M879.71M332.76M1.03B951.13M907.37M855.48M787.52M
Effective Tax Rate %28.36%22.94%-91.1%14.12%16.53%13.88%10%9.57%18.76%84.18%24.77%18.13%31.65%5.47%4.79%9.04%19.03%20.13%19.16%19.32%24.58%27.01%23.02%26.27%23.95%17.67%27%28%28%29%29.5%
Net Income4.7B6.52B13.4B5.72B6.93B7.07B4.5B3.69B2.37B477M1.4B4.42B2.28B2.58B5.96B4.73B4.63B5.75B4.88B3.61B1.72B3.37B3.24B2.75B2.79B1.55B2.79B2.45B2.33B2.08B1.88B
Net Margin %9.75%14.72%31.95%14.27%15.88%16.42%12.99%11.56%7.74%1.74%6.71%21.68%11.28%11.79%14.95%12.17%13.15%18.68%16.53%13.92%7.64%15.1%16.44%13.99%15.8%9.52%20.27%18.56%18.71%17.5%17.09%
Net Income Growth %-66.37%-51.32%134.18%-17.45%-1.95%57.31%21.91%55.7%396.44%-65.93%-68.35%93.65%-11.34%-56.8%26.12%2.2%-19.49%17.73%35.34%110.07%-49.09%4.21%17.53%-1.45%80.19%-44.35%13.91%4.77%12.28%10.47%11.45%
Net Income (Continuing)4.7B6.52B13.4B5.72B6.93B7.07B4.47B3.69B2.33B353M1.06B2.61B1.72B1.99B237M1.13B4.63B5.75B4.73B3.61B1.72B3.37B3.18B2.5B2.55B1.55B2.79B2.45B2.33B2.08B1.88B
Discontinued Operations00000024M034M124M337M1.82B563M588M0000000060.02M00000000
Minority Interest596M641M237M224M219M222M219M213M198M201M179M115M113M96M92.27M86.31M88.33M43.1M39.14M000000000000
EPS (Diluted)2.713.727.643.273.913.942.502.061.340.270.942.941.501.643.753.012.973.703.132.311.122.162.061.751.780.991.781.571.491.331.19
EPS Growth %-66.16%-51.31%133.64%-16.37%-0.76%57.6%21.36%53.73%396.3%-71.28%-68.03%96%-8.54%-56.27%24.58%1.35%-19.73%18.21%35.5%106.25%-48.15%4.85%17.71%-1.69%79.8%-44.38%13.38%5.37%12.03%11.76%12.26%
EPS (Basic)-3.747.673.303.943.972.522.071.350.270.953.001.511.663.783.012.993.723.162.341.122.172.071.761.791.001.801.591.521.351.21
Diluted Shares Outstanding1.74B1.75B1.75B1.75B1.76B1.79B1.79B1.78B1.77B1.75B1.48B1.51B1.53B1.57B1.59B1.57B1.56B1.55B1.56B1.56B1.54B1.56B1.57B1.57B1.57B1.57B1.57B1.56B1.56B1.58B1.58B
Basic Shares Outstanding1.73B1.75B1.73B1.73B1.75B1.77B1.77B1.77B1.76B1.74B1.47B1.47B1.51B1.55B1.58B1.57B1.55B1.55B1.54B1.54B1.53B1.55B1.56B1.56B1.56B1.55B1.55B1.54B1.54B1.55B1.56B
Dividend Payout Ratio-63.09%28.62%62.14%47.73%45.28%56.95%61.57%83.36%387.63%109.93%32.62%58.76%34.24%53.38%62.14%57.75%42.02%44.55%54.33%103.52%50.01%49.44%44%51.11%81.97%41.13%41.02%38.2%38.94%38.69%

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Legal and regulatory exposure concentration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Steadying Near Mid-Single Digits

According to the reported quarterly income statements, ABT's revenue grew 14.5% year over year in the latest quarter after 4.0% growth two years earlier, a pattern that suggests growth has been volatile rather than structurally accelerating across the ten-quarter window reviewed here. Investors should weigh whether the recent step-up is durable.

The quarterly series shows revenue expanding from roughly $10.4 billion to $13.0 billion, but the year-over-year rates swing sharply, which may reflect pricing, volume, or the roll-off of pandemic-related diagnostics sales rather than a single consistent driver. The 5.7% trailing growth figure in the peer context appears more representative of underlying momentum than the single-quarter spikes. Warranting further investigation is how much of the latest acceleration is organic versus timing-driven.

Gross Margin Expanding Within a Narrow Band

Based on reported figures, ABT's gross margin moved from 51.0% to 56.8% over the period, a structural improvement that may reflect mix shift toward higher-margin Medical Devices, though the magnitude remains below the 65% to 78% gross margins posted by MDT, BSX, and EW.

The 5 to 6 percentage point expansion is meaningful for a diversified conglomerate and suggests the Medical Devices and diabetes care franchises are contributing disproportionately to profit. However, the gap to pure-play medtech peers implies the Nutritionals and Established Pharmaceuticals segments continue to dilute blended margins. Investors should monitor whether further expansion is achievable without pricing concessions.

Operating Margin Recovery Lags Gross Expansion

As reported in the income statements, ABT's operating margin compressed to 10.4% in the latest quarter from 19.6% in the prior year's fourth quarter, indicating that operating expenses have been absorbing a growing share of gross profit despite expanding gross margins.

Operating income has declined in absolute terms across recent quarters even as gross profit held near $6.3 to $7.4 billion, which points to negative operating leverage rather than scaling efficiency. SG&A and R&D together appear to be rising faster than gross profit, a pattern that warrants scrutiny of overhead discipline. The gap versus the 18.2% trailing operating margin suggests the most recent quarter may contain elevated one-time or seasonal costs that should be verified.

Reported Earnings Volatility Obscures Core Trend

Based on reported figures, ABT's diluted EPS ranged from $0.53 to $5.27 across the ten quarters, with the $5.27 quarter in late 2024 likely distorted by non-operating or one-time items, making the reported earnings trajectory difficult to interpret without adjustment.

Net income in the 2024Q4 period of roughly $9.2 billion is wildly disproportionate to operating income of $2.0 billion, a discrepancy that suggests substantial non-operating gains or accounting adjustments. Stock-based compensation remains modest relative to revenue, so it does not explain the anomaly. Analysts should normalize earnings before drawing conclusions about profitability trends.

Short-Thesis Risks Center on Litigation and Compression

The strongest bear argument, based on reported quarterly figures, is that operating margin has fallen from roughly 18% to 10% in the most recent quarter while legal exposure accounts for about 32% of tracked risk factors, potentially signaling margin pressure that management has not yet explained.

If the latest operating margin reflects a durable shift rather than a temporary cost event, the current valuation may embed expectations the income statement does not yet support. Litigation tied to pediatric nutrition and device claims could add unquantified charges that the reported figures do not fully capture. The absence of forward guidance in the latest report leaves investors without management's view on whether this compression is transitory.

ABT — Frequently Asked Questions

Quick answers to the most common questions about buying ABT stock.

What was Abbott Laboratories's (ABT) revenue in 2025?

For fiscal year 2025, Abbott Laboratories (ABT) reported total revenue of $44.33B. This represents a 302.5% increase compared to $11.01B in 1996.

Is Abbott Laboratories (ABT) profitable?

Abbott Laboratories (ABT) is profitable, generating $6.52B in net income for the fiscal year ending 2025 with a net profit margin of 14.7%.

What is Abbott Laboratories's operating profit margin?

Abbott Laboratories (ABT) reported an operating income of $8.05B, resulting in an operating profit margin of 18.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Abbott Laboratories's gross profit and gross margin?

Abbott Laboratories (ABT) generated $24.61B in gross profit for the year, representing a gross profit margin of 55.5%. This demonstrates the company's core pricing power and production efficiency.